Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy

Table 1 Baseline and demographic characteristics of patients in this study

	First-line eradication therapy					Second-line eradication therapy
	VPZ group	PPI group	EPZ group	RPZ group	LPZ group	VPZ group	PPI group	EPZ group	RPZ group	LPZ group
	n = 546	n = 807	n = 507	n = 89	n = 211	n = 76	n = 185	n = 104	n = 24	n = 57
Age, mean ± SD, yr	57.4 ± 11.8	56.7 ± 12.8	56.9 ± 11.6	60.7 ± 11.2	56.1 ± 12.1	56.9 ± 12.8	56.0 ± 12.6	57.5 ± 12.5	58.2 ± 12.2	58.1 ± 12.3
Sex, n (%)
Male	225 (41.2)	318 (39.4)	193 (38.1)	35 (39.3)	90 (42.7)	30 (39.5)	71 (38.4)	39 (37.5)	9 (39.3)	23 (40.4)
Female	321 (58.8)	489 (60.6)	314 (61.9)	54 (60.7)	121 (57.3)	46 (60.5)	114 (61.6)	65 (62.5)	15 (60.7)	34 (59.6)
Indication
GU(s)	32	33	18	4	11	3	7	6	0	1
DU(s)	37	68	36	8	24	5	13	5	2	6
GDU(s)	4	4	2	1	1	1	0	0	0	0
MALT lymphoma	0	2	0	0	2	0	1	0	0	1
Post ESD	1	3	2	0	1	1	0	0	0	0
Atrophic gastritis	472	697	449	76	172	66	164	93	22	49

GU/GUs: Gastric ulcer and/or ulcer scar; DU/DUs: Duodenal ulcer and/or ulcer scar; GDU/GDUs: Gastroduodenal ulcer and/or ulcer scar; MALT: Mucosa-associated lymphoid tissue; ESD: Endoscopic submucosal dissection; VPZ: Vonoprazan; PPI: Proton pump inhibitor; EPZ: Esomeprazole; RPZ: Rabeprazole; LPZ: Lansoprazole.